Company Overview
STRATA Skin Sciences, Inc. operates as a medical technology company dedicated to the development, commercialization, and marketing of products designed for the treatment of dermatologic conditions across a global footprint that includes the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company functions within the broader Healthcare sector and specifically within the Medical Devices industry, a segment characterized by high regulatory barriers and significant capital investment requirements for product innovation and manufacturing. This entity manages a market capitalization of $1.48M and reported annual revenue of $30.70M based on trailing twelve-month figures, while specific employee headcount data is not disclosed in current filings. The relatively low market capitalization relative to the reported revenue suggests a small-cap positioning, indicating that the company is likely in an early growth phase or is facing challenges in scaling its commercial operations to match its top-line generation.
Financial Health
The company reported revenue of $30.70M over the trailing twelve months, yet generated a net income loss of $-6,261,000, creating a substantial gap that reveals a heavy cost structure where operating expenses significantly outpace gross profitability. EBITDA for the period stood at $-577,000, indicating that even before interest, taxes, depreciation, and amortization, the core operations generated a negative cash earnings figure. Free cash flow was negative at $-2,495,875, which implies limited financial flexibility and a reliance on external capital sources or cash reserves to fund day-to-day operations and strategic initiatives without generating internal cash sufficiency. The gross margin stands at 58.3%, suggesting that the cost of goods sold is well-controlled relative to sales, though this does not fully offset other operational costs. The operating margin is reported at 12.6%, while the profit margin is -20.4%, demonstrating that non-operating expenses or structural inefficiencies are eroding the bottom line despite a healthy gross margin. The company holds $7.91M in cash but carries $16.27M in debt, resulting in a debt-to-equity ratio of 559.42, which indicates a highly leveraged balance sheet where liabilities substantially exceed equity. The current ratio is 0.58, signaling potential short-term liquidity constraints as current assets are insufficient to cover current liabilities without refinancing or asset liquidation. Return on Equity is -158.9% and Return on Assets is -8.8%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -0.20, a metric that is technically undefined for profitable firms but here reflects the negative earnings outlook rather than a standard valuation multiple. The price-to-book ratio is 0.53, indicating that the market values the company at less than half of its net asset value, which often signals deep value potential or significant concerns regarding the quality and realizability of those assets. The price-to-sales ratio is 0.05, a very low multiple that suggests the market assigns minimal value to each dollar of revenue, reflecting high perceived risk or a lack of confidence in future profitability. The EV/EBITDA multiple is -17.14, which further underscores the company's negative earnings position and the inability to use traditional enterprise value metrics for standard comparison with profitable peers. The stock has traded between a 52-week high of $3.86 and a 52-week low of $0.12, illustrating extreme volatility and a significant depreciation in share price over the last year. Without a specific current share price provided in the facts to calculate the exact percentage distance from the high or low, the wide range between $3.86 and $0.12 highlights the substantial risk premium demanded by the market for this speculative asset. The beta is N/A, meaning volatility data relative to the broader market is not available to quantify the stock's sensitivity to market movements.
Growth & Income
Revenue growth year-over-year is -3.0%, indicating a contraction in top-line sales, while earnings growth is N/A due to the lack of comparable positive earnings data in the previous period. The negative revenue growth suggests the company is losing market share or failing to gain traction with its dermatologic products, a trend that is not being offset by any improvement in cost efficiency. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested into operations, though the current net loss prevents any meaningful reinvestment of profit. Consequently, the overall growth and income profile is characterized by declining revenue and an absence of income distribution, relying entirely on external financing to sustain operations in the absence of organic growth or profitability.